NRX Pharmaceuticals (NRXP) Non-Current Debt (2018 - 2021)

NRX Pharmaceuticals (NRXP) has 4 years of Non-Current Debt data on file, last reported at $1.4 million in Q1 2021.

• On a quarterly basis, Non-Current Debt fell 15.43% year-over-year to $1.4 million in Q1 2021; TTM through Mar 2021 was $1.4 million, a 15.43% decrease from a year earlier, with the FY2019 full-year figure at $416141.0, down 39.69% from the prior year.
• Non-Current Debt for Q1 2021 stood at $1.4 million, up from $758060.0 in the prior quarter.
• Over the last five years, Non-Current Debt for NRXP reached as high as $1.7 million in Q2 2020 and fell as low as $327198.0 in Q3 2019.
• Historically, Non-Current Debt has averaged $1.1 million across 4 years, with a median of $1.4 million in 2019.
• Across the five-year window, Non-Current Debt sank 39.69% in 2019 and jumped 131.68% in 2020, its largest moves.
• Year by year, Non-Current Debt stood at $690000.0 in 2018, then sank by 39.69% to $416141.0 in 2019, then surged by 82.16% to $758060.0 in 2020, then surged by 82.04% to $1.4 million in 2021.
• Per Business Quant data, the three most recent Non-Current Debt figures were $1.4 million in Q1 2021, $758060.0 in Q3 2020, and $1.7 million in Q2 2020.